Clinical Trial

Dose-Response Impact of Glucosyl-Hesperidin (CitraPeak) on Exercise Performance, Blood Flow, Stress, Cognition, and Other Perceptual Indicators

Study acronym: HES
Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated December 12, 2025 (before its estimated January 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
The purpose of this study is to evaluate the dose-dependent effects of glucosyl-hesperidin (CITRAPEAK) supplementation on exercise performance, recovery indicators, blood flow, cognitive function, mood, sleep, and fuel utilization in recreationally active adults.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-11-01.
Status change: Not Yet Recruiting → Recruiting 2025-12-05
Trial Details
NCT Number NCT06672952
Lead Sponsor Lindenwood University
Collaborators: Increnovo LLC
Conditions Exercise Performance, Exercise Recovery, Cognitive Function, Nitric Oxide, Blood Flow, Endurance Exercise
Enrollment 60 participants
Start Date 2025-04-15
Primary Completion 2026-01-01 (estimated)
Study Completion 2026-01-01 (estimated)
Updated on ClinicalTrials.gov 2025-12-12